COL1A1
COL1A1 (Collagen alpha-1(I) chain) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Sarcomas, Anal cancer, Pancreatic ductal adenocarcinoma and 3 more.
Overview
Type I collagen is a member of group I collagen (fibrillar forming collagen).
Open Targets scores its association with cancer at 0.67 (direct and indirect evidence; datatypes literature 0.98, animal model 0.57, genetic association 0.00, somatic mutation 0.79). IntOGen calls it a driver in 5 cohorts (2 activating, 3 loss-of-function), covering Anal Squamous Cell Carcinoma, Glioblastoma Multiforme, Melanoma, Pancreatic Adenocarcinoma, Plasma Cell Myeloma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · COL1A1 (Collagen alpha-1(I) chain) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Sarcomas, Anal cancer, Pancreatic ductal adenocarcinoma and 3 more.
- 1 · What it is
COL1A1 (Collagen alpha-1(I) chain) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Sarcomas, Anal cancer, Pancreatic ductal adenocarcinoma and 3 more.
- 2 · What goes wrong in cancer
Type I collagen is a member of group I collagen (fibrillar forming collagen). Location: Secreted, extracellular space, extracellular matrix (UniProt).
- 3 · How drugs use it
No product in this corpus aims at COL1A1 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
External identifiers
Sources: HGNC HGNC:2197 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P02452 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000108821 (association with cancer (MONDO_0004992) 0.67; per-cancer scores at or above 0.5: sarcoma 0.59 (GraphQL API, CC0)); IntOGen COL1A1 (driver in 5 cohorts (Act 2, LoF 3); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Type I collagen is a member of group I collagen (fibrillar forming collagen). Location: Secreted, extracellular space, extracellular matrix (UniProt). Locus 17q21.33 (HGNC).
- Sarcomas: Open Targets association 0.59 with sarcoma (MONDO_0005089)
- Anal cancer: IntOGen driver in 1 cohort (ANSC)
- Pancreatic ductal adenocarcinoma: IntOGen driver in 1 cohort (PAAD)
- Multiple myeloma: IntOGen driver in 1 cohort (PCM)
- Glioma & glioblastoma: IntOGen driver in 1 cohort (GBM)
- Melanoma: IntOGen driver in 1 cohort (MEL)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 2 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 3 cohorts; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"COL1A1" OR ABSTRACT:"COL1A1" OR TITLE:"collagen type I alpha 1 chain" OR ABSTRACT:"collagen type I alpha 1 chain" OR TITLE:"Collagen alpha-1 I chain" OR ABSTRACT:"Collagen alpha-1 I chain" OR TITLE:"OI4" OR ABSTRACT:"OI4") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about COL1A1, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetPTPRC
Shares Anal cancer (squamous cell carcinoma), IntOGen, Melanoma, Open Targets Platform.
- TargetBIRC6
Shares Anal cancer (squamous cell carcinoma), IntOGen, Open Targets Platform.
- CompanyOncolytics Biotech
Shares Anal cancer (squamous cell carcinoma), Pancreatic ductal adenocarcinoma.
- JournalClinical colorectal cancer
Shares Anal cancer (squamous cell carcinoma), Pancreatic ductal adenocarcinoma.
- TrialA Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab
Shares Anal cancer (squamous cell carcinoma), Pancreatic ductal adenocarcinoma.
- TargetSTK11
Shares Anal cancer (squamous cell carcinoma), IntOGen, Pancreatic ductal adenocarcinoma, Open Targets Platform.
- TargetAPC
Shares Anal cancer (squamous cell carcinoma), IntOGen, Open Targets Platform.
- JournalJournal of gastrointestinal cancer
Shares Anal cancer (squamous cell carcinoma), Pancreatic ductal adenocarcinoma.